Compare Crispr Therapeutics AG (CRSP) vs Tenet Healthcare Corporation (THC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Tenet Healthcare Corporation — how do they compare? Crispr Therapeutics AG trades at $53.39 (market cap $4.88B), while Tenet Healthcare Corporation trades at $263.78 (market cap $20.98B). The key difference: Tenet Healthcare Corporation is far larger — about 4.3× Crispr Therapeutics AG's market cap, and Tenet Healthcare Corporation is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Tenet Healthcare Corporation for 15 Days on average.
| CRSP | THC | |
|---|---|---|
Market Cap | $4.88B | $20.98B |
Volume | 2,861,747 | 428,008 |
Sector | Health | Health |
52-Week High | $74.92 | $280.77 |
52-Week Low | $44.34 | $161.37 |
Typical Hold Time | 77 Days | 15 Days |
Enterprise Value | $3.30B | $32.06B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $50.44, down 3.65% amid bearish technical signals. The company shows negative profitability with -$581.60M net income and -4,101.26% net margin for 2025, though Q2 2026 EPS beat expectations. Positive analyst sentiment persists with 57.9% buy ratings and $67.83 consensus target. Recent clinical data presentations and CASGEVY commercial progress provide catalysts.
The stock faces fundamental challenges with persistent losses and negative cash flow from operations, but maintains Wall Street support for its gene-editing pipeline. Key risks include clinical trial outcomes and cash burn, while potential upside hinges on successful drug commercialization and upcoming data readouts through 2026.
Tenet Healthcare (THC) trades at $260.57, showing modest daily gains of 0.28% with strong technical support at $257 and resistance at $262. The stock demonstrates robust fundamentals with a P/E of 10.07, net income margin of 9.9%, and consistent earnings beats in recent quarters. Recent news highlights the upcoming Q3 2026 earnings release on October 29, 2026, while the company maintains strong cash flow generation of $3.54 billion from operations.
THC presents a compelling investment case with 81% analyst buy ratings and a $283.36 consensus price target representing 8.7% upside potential. The company's expanding capital return strategy and projected revenue growth to $22.6 billion in 2026 support bullish sentiment, though investors should monitor surgical volume trends and capital allocation sustainability as key risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Tenet Healthcare Corporation
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →
